We speculate that there exists an association of this genetic variant with a decreased risk of cancer at a global level, and MM and MS at a local level, due to a decrease in TPCN2 expression that has been shown to be functionally expressed in different types of cancer, using the Human Protein Atlas. The gene discussed is TPCN2; the disease is myeloid sarcoma.